A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer

Table 3 Non-hematologic Toxicities

Toxicity	Grade 1 N (%)	Grade 2 N (%)	Grade 3 N (%)	Grade 4 N (%)	Grade 5 N (%)
Dyspnea		2 (33.3%)	2 (33.3%)	1 (16.7%)
Respiratory Failure				1 (16.7%)	1 (16.7%)
Upper Respiratory Infection		1 (16.7%)
Cough		1 (16.7%)	1 (16.7%)
Pneumonia				1 (16.7%)
Hallucinations			1 (16.7%)
Dehydration	1 (16.7%)		1 (16.7%)
Hypotension		1 (16.7%)	1 (16.7%)
Dermatology, Other (Heating pad burn)	1 (16.7%)
Pain		1 (16.7%)	1 (16.7%)	1 (16.7%)
Peripheral Neuropathy	1 (16.7%)
Hyperglycemia	1 (16.7%)
Infection		1 (16.7%)
Sore throat	1 (16.7%)
Flu-like symptoms	1 (16.7%)
Fatigue	1 (16.7%)	4 (66.7%)
Arthralgia	1 (16.7%)
Headache	1 (16.7%)
Fever	2 (33.3%)
Decreased level of consciousness			1 (16.7%)
Nausea/Vomiting	1 (16.7%)
Hyponatremia				1 (16.7%)
Hypoxia			1 (16.7%)
Syncope			1 (16.7%)
Rash	1 (16.7%)
Injection site reaction^a	1 (16.7%)
Infection, Other (Lip)^b		1 (16.7%)
Dizziness	1 (16.7%)
Constipation	1 (16.7%)
Hypoalbuminemia		1 (16.7%)

^aAttributed to DRibble vaccine
^bAttributed as unlikely related to DRibble vaccine
All other toxicities were attributed as unrelated to DRibble vaccine, but were considered related to docetaxel or underlying disease